Dec. 1 (Bloomberg) -- Novartis AG’s vaccine unit is interested in acquisitions that enable global expansion rather those that provide new products, Finanz und Wirtschaft said, citing an interview with the unit’s head, Andrin Oswald.
The size of a possible acquisition could be between $100 million and $200 million, the newspaper cited Oswald as saying. Novartis doesn’t need to buy vaccine products because it has a full pipeline, Oswald is quoted as saying in the newspaper.
To contact the reporter on this story: Eva von Schaper in Munich at email@example.com;
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org.